1. Academic Validation
  2. Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARγ signaling pathway

Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARγ signaling pathway

  • Ann Transl Med. 2021 Oct;9(20):1547. doi: 10.21037/atm-21-4764.
Liqiang Chen 1 Yajuan Yin 2 Gang Liu 2
Affiliations

Affiliations

  • 1 Cardiovascular Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • 2 Cardiovascular Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Abstract

Background: Previous studies have reported that the combination of metformin and bevacizumab exhibit favorable efficacy in the treatment of Cancer patients, and metformin possesses effects on relieving vascular injury in multiple diseases. Nonetheless, the effect of metformin in alleviating bevacizumab-induced vascular injury remains unknown. Therefore, the present study aimed to investigate the impact of metformin on Apoptosis, vascular endothelial injury marker expressions, and inflammation in human umbilical vein endothelial cells (HUVECs), as well as its possible molecular mechanism.

Methods: HUVECs were treated with bevacizumab, metformin or both, and subsequently treated with Growth Differentiation Factor 15 (GDF15) overexpression plasmid, negative control (NC) plasmid, GDF15 small interfering ribonucleic acid (siRNA), NC siRNA, and the phosphoinositide 3-kinase (PI3K) inhibitor LY294002, respectively. After treatment, Apoptosis, levels of endothelial injury biomarkers and the potential downstream proteins were detected.

Results: Bevacizumab increased the levels of Apoptosis, vascular endothelial injury marker expressions and pro-inflammatory cytokine expressions in HUVECs, while metformin alleviated these effects in bevacizumab-treated HUVECs. Furthermore, GDF15 overexpression reduced the Apoptosis, vascular endothelial injury marker expressions, pro-inflammatory cytokine expressions, and activated the PI3K/protein kinase B (Akt)/forkhead box O (FOXO)/Peroxisome Proliferator-activated Receptor γ (PPARγ) signaling pathway in bevacizumab-treated HUVECs. Subsequently, GDF15 siRNA reduced the effects of metformin on the bevacizumab-induced vascular endothelial injury (as described above) in HUEVCs. Lastly, the PI3K Inhibitor exhibited similar effects to those of GDF15 siRNA in bevacizumab-treated HUVECs.

Conclusions: Metformin protected against bevacizumab-induced vascular endothelial injury via activation of GDF15 and the PI3K/Akt/FOXO/PPARγ signaling pathway.

Keywords

GDF15; PI3K/AKT/FOXO/PPARγ signaling pathway; Vascular endothelial injury; bevacizumab; metformin.

Figures
Products